AMS X

3DPOD Episode 59: PostProcess CEO Jeff Mize

Formnext
IMTS

Share this Article

Jeff Mize is a veteran entrepreneur who sold his firm NAVTEQ to Nokia for $8.1 billion and his Climate Corporation to Monsanto for $1.1 billion. He now heads up PostProcess Technologies. There, Jeff wants to help 3D printed goods become a reality through a number of post-processing solutions. With a variety of technologies with exciting names, Post Process helps remove SLA supports, de-powder SLS builds, and surface finish parts. We talked about Jeff’s goals for the company and how he sees the industry grow and change. I think that both Max and I learned a lot from Jeff and hope that you will as well.



Share this Article


Recent News

3D Printing News Briefs, August 8, 2026: Seawall Funding, Defense Capabilities, Supports, & More

Eplus3D & UCL Rocket Test New LOX IPA Engine



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

Dawn Aerospace Raises $25 Million as 3D Printing Helps Power Reusable Spaceflight Ambitions

The race to build the next generation of reusable spacecraft just got another boost. Dawn Aerospace has landed $25 million in Series B funding to help scale its reusable space...

ETH Students 3D Print Experimental Rocket Engine

Students at the Swiss University ETH have built a Rotating Detonation Rocket Engine (RDRE). An RDRE burns propellant in a ring-shaped combustion chamber where a continuous supersonic wave detonation is...

AMPulse Asia: APAC 3D Printing Market Roundup

Key Takeaways Coverage window: April 27 to May 10, 2026. Roughly 30 additive manufacturing (AM)-relevant announcements were tracked across eight Asia-Pacific countries. Largest disclosures: Farsoon Technologies (688433.SH) filing a RMB...

3D Printing News Briefs: May 7, 2026: Metal Powder Bed Fusion, Surgical Plates, & More

In today’s 3D Printing News Briefs, we’ll start with a strategic collaboration to advance next-generation metal additive manufacturing (AM), before moving on to funding for surgical research. We’ll end with...